Bioequivalence Study of Idalopirdine Tablets 60 mg
Launched by H. LUNDBECK A/S · Feb 20, 2015
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy men and women
- • -≥18 and ≤55 years of age
- • body mass index (BMI) of \>18.5 and \<30 kg/m2
- Exclusion Criteria:
- • Pregnant and lactating women
- • Other protocol defined inclusion and exclusion criteria may apply
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, , United Kingdom
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Study Director
LundbeckClinicalTrials@Lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials